SELLAS Life Sciences Group Inc SLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
-
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
-
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
-
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
-
Sellas Life Sciences Gets Favorable Meeting Feedback From FDA
-
Sellas Life Sciences Shares Rise 7.6% on Fast Track Designation for Cancer Treatment by FDA
-
Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia
Trading Information
- Previous Close Price
- $1.24
- Day Range
- $1.20–1.26
- 52-Week Range
- $0.50–1.72
- Bid/Ask
- $1.24 / $1.26
- Market Cap
- $79.77 Mil
- Volume/Avg
- 430,074 / 633,936
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Comparables
Valuation
|
Metric
|
SLS
|
ARTV
|
CCCC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 24.59 | — | 1.51 |
Price/Sales | — | 4.36 | 10.98 |
Price/Cash Flow | — | — | — |
Price/Earnings
SLS
ARTV
CCCC
Financial Strength
|
Metric
|
SLS
|
ARTV
|
CCCC
|
|---|---|---|---|
Quick Ratio | 0.76 | 4.43 | 4.89 |
Current Ratio | 1.02 | 4.59 | 5.09 |
Interest Coverage | — | — | −715.67 |
Quick Ratio
SLS
ARTV
CCCC
Profitability
|
Metric
|
SLS
|
ARTV
|
CCCC
|
|---|---|---|---|
Return on Assets (Normalized) | −224.99% | −16.21% | −22.53% |
Return on Equity (Normalized) | −2,890.63% | — | −34.97% |
Return on Invested Capital (Normalized) | −1,747.48% | — | −30.08% |
Return on Assets
SLS
ARTV
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fcxvgbjnd | Lkl | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cncfxhwzx | Qcmfmp | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wrhrjcgb | Byffwk | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Byczcbplt | Yrwvsl | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Wtjtxdyg | Chnx | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Xxpdsyfb | Jyp | $28.3 Bil | |||
| Moderna Inc
MRNA
| Dgdjkcqyl | Bztw | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Wrczjfqk | Rcbz | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bnpgltbd | Gwmxxmt | $13.3 Bil | |||
| Incyte Corp
INCY
| Mzzftwft | Dtzyc | $13.0 Bil |
United States